Online Webinars

Late Breaking Data from the Society for Immunotherapy of Cancer 2016

EVENT DATE: Dec 6, 2016
EVENT SPEAKERS: Dr. Sonja Althammer, Bioinformatics Team Lead, Definiens AG

Immunotherapies have improved patient responses and survival, though not all patients benefit. Effective biomarkers may help improve outcomes. Durvalumab is a human IgG1 monoclonal antibody that inhibits programmed death ligand-1 (PD-L1) binding to programmed death-1 and B7.1/CD80, restoring antitumor immunity. PD-L1 expression on tumor or tumor-infiltrating immune cells measured manually with different immunohistochemistry (IHC) assays can enrich for patients responding to anti-PD1/PD-L1 agents. Tumor-infiltrating cytotoxic CD8+ T cells may also have potential predictive utility for therapeutic response. We explored automated image analysis and pattern recognition of tumor biopsies to determine whether CD8+ and PD-L1+ cells densities could better identify patients most likely to respond to durvalumab than PD-L1 IHC alone.

In this webinar, Dr Althammer will demonstrate:

  • How Tissue Phenomics® can support you to quantify different cell populations based on multiple biomarker expression profiles (CD8(+) and PD-L1(+)) and to further investigate correlations of the density of those populations to the clinical data
  • How Tissue Phenomics® has been used to detect the improved predictive value for Durvalumab treatment by combining CD8 and PD-L1 evaluation compared to PD-L1 alone

The presentation represents the team effort of groups at DEFINIENS and MedImmune and was recently presented at the SITC conference.